4-Hydroxytamoxifen trans-represses nuclear factor-κB activity in human osteoblastic U2-OS cells through estrogen receptor (ER)α, and not through ERβ

Endocrinology

Volumn 142, Issue 3, 2001, Pages 1156-1166

  Quaedackers, Monique E ^a   Van Den Brink, Christina E ^a   Wissink, Sacha ^a   Schreurs, Richard H M M ^a   Gustafsson, Jan Åke ^b   Van Der Saag, Paul T ^a   Van Der Burg, Bart ^a  

^a HUBRECHT INSTITUTE   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; CELL CULTURE; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE REPRESSION; HUMAN; HUMAN CELL; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0035096353     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.142.3.8003     Document Type: Article

References (64)

1. Toward a molecular understanding of skeletal development
2. Bone morphogenesis and modeling: Soluble signals sculpt osteosomes in the solid state
3. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men
4. Treatment of postmenopausal osteoporosis
5. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton
6. Cloning of the human estrogen receptor cDNA
7. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
8. ERβ: Identification and characterization of a novel human estrogen receptor
9. The complete primary structure of human estrogen receptor β (hER β) and its heterodimerization with ER α in vivo and in vitro
10. Molecular mechanism of action of steroid/thyroid receptor superfamily members
11. The human estrogen receptor has two independent nonacidic transriptional activation functions
12. A novel, cell-type-specific mechanism for estrogen receptor-mediated gene activation in the absence of an estrogen-responsive element
13. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells
14. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
15. Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-α 1 promoter via a novel sequence
16. Function and activation of NF-κB in the immune system
17. Down-modulation of interleukin-6 gene expression by 17 β-estradiol in the absence of high affinity DNA binding by the estrogen receptor
18. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBP β
19. Involvement of CCAAT/enhancer-binding protein and nuclear factor-κB binding sites in interleukin-6 promoter inhibition by estrogens
20. Molecular control of immune/inflammatory responses: Interactions between nuclear factor-κB and steroid receptor-signaling pathways
21. Repression of nuclear factor-κB activity as a functional basis of anti-inflammation and immonusuppression by glucocorticoids
22. A dual mechanism mediating repression of NF-κB activity by glucocorticoids
23. The protective effects of estrogen on the cardiovascular system
24. Estrogen actions in the central nervous system
25. Combined continuous hormone replacement therapy: A critical review
26. The role of tamoxifen in the treatment and prevention of breast cancer
27. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
28. Transcription activation by the human estrogen receptor subtype β (ER β) studied with ERβ and ER α receptor chimeras
29. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors
30. Development of a stably transfected estrogen receptor-mediated luciferase reporter gene assay in the human T47D breast cancer cell line
31. NF-κ B/Rel family members regulating the ICAM-1 promoter in monocytic THP-1 cells
32. Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: Synergistic action of insulin and estrogen
33. Nuclear retinoic acid receptors: Cloning, analysis, and function
34. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
35. Analysis and interpretation of binding at equilibrium
36. Risks and benefits of tamoxifen therapy
37. In vitro sensitivity test of breast cancer cells to hormonal agents in a radionucleotide-incorporation assay
38. Negative cross-talk between ReIA and the glucocorticoid receptor: A possible mechanism for the antiinflammatory action of glucocorticoids
39. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids
40. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis
41. Estrogen inhibits phorbol ester-induced IκBα transcription and protein degradation
42. Repression of interleukin-6 gene expression by 17β-estradiol: Inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-κB by the estrogen receptor
43. Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site
44. Characterization of mechanisms of interleukin-6 gene repression by estrogen receptor
45. Agonistic effect of tamoxifen is dependent on cell type. ERE-promoter context, and estrogen receptor subtype: Functional difference between estrogen receptors α and β
46. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
47. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
48. Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability
49. The mechanism of ICI-164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue
50. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions
51. Molecular basis of agonism and antagonism m the oestrogen receptor
52. Comparison of the ligaod binding specificity and transcript tissue distribution of estrogen receptors α and β
53. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β
54. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
55. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β
56. Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist
57. Estrogen receptor null mice: What have we learned and where will they lead us?
58. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERβ(-/-) mice
59. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
60. Differential expression of estrogen receptors α and β mRNA during differentiation of human osteoblast SV-HFO cells
61. Mouse estrogen receptor β forms estrogen response element-binding heterodimers with estrogen receptor α
62. Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor α